Venus Remedies is currently trading at Rs. 162.85, up by 2.15 points or 1.34% from its previous closing of Rs. 160.70 on the BSE.
The scrip opened at Rs. 161.00 and has touched a high and low of Rs. 167.85 and Rs. 159.35 respectively. So far 1791 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 10 has touched a 52 week high of Rs. 378.90 on 11-Apr-2022 and a 52 week low of Rs. 145.00 on 08-Feb-2023.
Last one week high and low of the scrip stood at Rs. 174.00 and Rs. 146.05 respectively. The current market cap of the company is Rs. 222.36 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.07% and 57.17% respectively.
Venus Remedies has received good manufacturing practices (GMP) certification from Saudi Arabia for all its production facilities at its unit in Baddi, Himachal Pradesh.
The Saudi Food and Drug Authority (SFDA) granted the certification, which included first time approval for pre-filled Enoxaparin syringes and general injection facilities, and renewed approval for Cephalosporin and Carbapenem antibiotics and liquid and lyophilised oncology drugs, after an extensive review and audit of the company’s facilities.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. It has world-class manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and research and development center in Venus Medicine Research Centre (in India).